AstraZeneca Pharma India Limited (BOM:506820)
India · Delayed Price · Currency is INR | Market Cap | 211.74B |
| Revenue (ttm) | 18.55B |
| Net Income (ttm) | 1.83B |
| Shares Out | 25.00M |
| EPS (ttm) | 73.33 |
| PE Ratio | 115.50 |
| Forward PE | n/a |
| Dividend | 32.00 (0.38%) |
| Ex-Dividend Date | Jul 18, 2025 |
| Volume | 620 |
| Average Volume | 1,627 |
| Open | 8,470.00 |
| Previous Close | 8,322.70 |
| Day's Range | 8,284.10 - 8,502.00 |
| 52-Week Range | 6,222.35 - 10,653.05 |
| Beta | 0.13 |
| RSI | 40.79 |
| Earnings Date | Aug 8, 2025 |
About AstraZeneca Pharma India
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally. It provides medicines for cardiovascular, renal, metabolic, and immunological conditions; oncology medicines under the TAGRISSO, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and respiratory medicines under the Symbicort and Fasenra brand names. The company also offers medicines for diabetes; and clinical trial services. The company... [Read more]
Financial Performance
In 2024, AstraZeneca Pharma India's revenue was 17.16 billion, an increase of 32.48% compared to the previous year's 12.96 billion. Earnings were 1.16 billion, a decrease of -28.34%.
Financial StatementsNews
AstraZeneca Pharma shares rise over 2% after company swings back to profit in Q1
Shares of AstraZeneca Pharma India surged 2.36% to Rs 8,615 on Thursday after the company reported a strong set of numbers for the quarter ended June 30, 2025. The stock gained Rs 198.50 from its prev...
AstraZeneca Pharma Q1 Results: Revenue up 36% YoY to Rs 526 crore, Net Profit at Rs 55 crore
AstraZeneca Pharma India reported a robust performance in the quarter ended June 30, 2025, with revenue from operations rising to Rs 526.3 crore, a sharp increase from Rs 387.5 crore in the same perio...
AstraZeneca Pharma gets CDSCO approval to import and sell Imfinzi for additional indication
AstraZeneca Pharma India Ltd. has received approval from the Central Drugs Standard Control Organisation (CDSCO) to import and sell Durvalumab Solution for Infusion (Imfinzi) for an additional indicat...
AstraZeneca Pharma India shares rally over 7% after strong Q4 results
Shares of AstraZeneca Pharma India surged 7.07% to ₹8,535.50 in early trade on Monday, June 2, after the company posted robust financial results for Q4 FY25 and announced a major revenue milestone. Th...
AstraZeneca Pharma receives CDSCO nod for expanded use of Fasenra in India
AstraZeneca Pharma India Limited has received approval from the Central Drugs Standard Control Organisation (CDSCO) to import and distribute Benralizumab (brand name: Fasenra) in India for an addition...
AstraZeneca Pharma gets approval for additional indication of Durvalumab (Imfinzi) in India
AstraZeneca Pharma India Limited has received approval from the Central Drugs Standard Control Organisation (CDSCO), India, to import, sell, and distribute Durvalumab (Imfinzi) solution for infusion i...
AstraZeneca receives approval to import Lokelma for hyperkalaemia treatment in India
AstraZeneca Pharma India Limited has received regulatory approval from the Central Drugs Standard Control Organisation (CDSCO), Directorate General of Health Services, Government of India, to import a...
AstraZeneca receives approval to import and distribute Eculizumab
AstraZeneca Pharma India Limited has announced that it has received regulatory approval to import and distribute Eculizumab concentrate for solution (300 mg, 10mg/ml) under the brand name SOLIRIS. Thi...
AstraZeneca Pharma India gets sale approval for additional indication of Olaparib film-coated tablets
AstraZeneca Pharma India Limited has received significant regulatory approval under Form CT-20 from the Central Drugs Standard Control Organisation (CDSCO). This allows the company to import, sell and...
Astrazeneca Pharma India shares surge 3% on Breztri Aerosphere launch announcement
AstraZeneca Pharma India Ltd saw its shares rise by 3% after announcing the launch of Breztri Aerosphere in January 2025. The company has received approval from the Drugs Controller General of India (...
AstraZeneca Pharma India to launch Breztri Aerosphere in January 2025
AstraZeneca Pharma India Limited has announced the upcoming launch of Breztri Aerosphere in January 2025. This innovative inhalation therapy combines Budesonide Ph. Eur 160 mcg, Glycopyrronium Ph. Eur...
AstraZeneca Pharma India shares surge over 8% amid focus on cancer projects and clinical trials
Shares of AstraZeneca Pharma India Ltd. witnessed a sharp rise of 8.26% on October 7, trading at ₹8,051. The stock opened at ₹7,440, surged to an intraday high of ₹8,129.95, and has been moving positi...
AstraZeneca Pharma surges over 7%, hits 52-week high during early trades
AstraZeneca Pharma India Ltd witnessed a significant surge in its stock price, rising over 7% to ₹7,697 as of 10:11 AM today. The stock opened at ₹7,150, reached a high of ₹7,743, and recorded a low o...
AstraZeneca gets nod to launch cancer drug
AstraZeneca Pharma India has received approval from the Central Drugs Standard Control Organisation to import Durvalumab for sale and distribution. The drug, combined with chemotherapy, treats resecta...